Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin - Seite 2

The Psyence Biomed study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context. Adjustment Disorder is a serious condition affecting approximately 19% of patients with a life-limiting diagnosis. It severely impacts the quality of life for patients, their families and caregivers, and regularly ranks among the top seven psychiatric diagnoses in the world, according to the World Health Organization (WHO).

Dr. Maresky added, “Developing therapies such as psilocybin-assisted psychotherapy, which may reduce patients’ stress and anxiety and result in better quality of life as they navigate a cancer diagnosis, can be very impactful. With psilocybin-assisted psychotherapy, there is an opportunity to both improve patient quality of life while also reducing health care costs associated with Palliative Care.”

Palliative Care is also increasingly recognized by the oncology community as a solution to stretching scarce health care resources. According to a separate report this month in the Journal of Clinical Oncology, the ASCO journal, “Randomized controlled trials have demonstrated that Palliative Care can improve quality of life and survival for outpatients with advanced cancer.” The JCO study found that with Palliative Care, hospitalizations decreased 18.7%.

Neither Psyence Biomedical nor any of its investors or affiliates funded or in any way sponsored the Hebrew University study. The full text of the paper can be found here: https://link.springer.com/content/pdf/10.1038/s41380-024-02477-w.pdf

The JCO paper can be found here: https://ascopubs.org/doi/10.1200/OP.23.00576

About Psyence Biomed:
Psyence Biomedical Ltd. is a life science biotechnology company listed on Nasdaq (Nasdaq:PBM), with a focus on natural psychedelics. The Company is developing nature-derived psilocybin mushroom products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research. We work to develop advanced natural psilocybin products for clinical research and development.